WeTrials
Recruiting

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

What is this study?

This study is testing an experimental medication called BAY 2927088 for people with advanced non-small cell lung cancer that has specific gene mutations. The goal is to see how safe the drug is, find the right dose, and check if it can help stop the cancer from growing.

Who can participate?

You may be able to join if you have advanced non-small cell lung cancer with specific EGFR or HER2 genetic mutations that has worsened after prior treatments. There are also health and timing requirements regarding past therapies to ensure the study is a safe fit for you.

What will happen?

Participants will take the study medication by mouth as a pill or liquid in 3-week cycles for as long as it is helping and safe. You will visit the clinic regularly for check-ups, blood and urine tests, and imaging scans like CT or MRI to monitor your health and cancer.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in Arizona, California, and Georgia within the United States.

Key Points
  • 1Tests a new targeted medication called BAY 2927088 for specific types of lung cancer.
  • 2Involves taking study medicine by mouth and attending regular check-ups and imaging scans.
  • 3Currently recruiting patients at select medical centers in the United States.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.

An Open Label, First-in-human Study of BAY 2927088 in… | WeTrials Trial Guide